622867-53-2

Basic information

• Product Name: 6-bromomethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester
• Synonyms: 6-bromomethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester
• CAS NO: 622867-53-2
• Molecular Weight: 326.233
• Mol File: 622867-53-2.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 6-bromomethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromomethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester(622867-53-2)
• EPA Substance Registry System: 6-bromomethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester(622867-53-2)

Safety Data

• Hazardous Substances Data: 622867-53-2(Hazardous Substances Data)

Upstream product

• 371222-37-6 N-t-butoxycarbonyl 1,2,3,4-tetrahydroisoquinoline-6-formaldehyde 
• 170097-67-3 2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 
• 622867-52-1 6-hydroxymethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 170097-66-2 3,4-Dihydro-1H-isoquinoline-2.6-dicarboxylic acid 2-tert-butyl ester-6-methyl ester 

Downstream Products

• 1398414-96-4 C₂₉H₃₀N₄O₃ 
• 1398412-09-3 5-methyl-1-[6-[3-methyl-2-[(2-tetrahydropyran-4-yl-3,4-dihydro-1H-isoquinolin-6-yl)methoxy]phenyl]-2-pyridyl]imidazole-4-carboxylic acid 
• 1398414-95-3 C₃₄H₃₈N₄O₅ 
• 1579517-50-2 C₃₆H₄₂N₄O₆ 
• 1579517-52-4 C₃₁H₃₄N₄O₄ 

Relevant articles and documents

PLASMA KALLIKREIN INHIBITORS

The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS

The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.

RAPAMYCIN ANALOGS AS MTOR INHIBITORS

The present disclosure relates to rapamycin analogs of the general Formula (I). The compounds are inhibitors of mTOR and thus useful for the treatment of cancer, immune-mediated diseases and age related conditions.